Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a con ...

Shares of Nektar Therapeutics (NKTR) have gained 79.9% over the past four weeks to close the last trading session at $68.42, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $129.86 indicates a potential upside of 89.8%.The mean estimate comprises seven short-term price targets with a standard deviation of $25.1. While the lowest estimate of $102.00 indicates a 49.1% increase fro ...

Nektar Therapeutics to Participate in Two Investor Conferences in March [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami.- 2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 – co ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NKTR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any i ...

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced an academic research collaboration with the University of California, San Francisco (UCSF) and Stephen L. Hauser, M.D., Robert A. Fishman Distinguished Professor of Neurology and Director of the UCSF ...

Core Insights - Nektar Therapeutics has successfully closed a public offering of $460 million, which includes the full exercise of underwriters' option to purchase additional shares [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing innovative medicines in immunotherapy [1] - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), which is being evaluated in multiple Phase 2 clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus [1] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [1] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist, in several ongoing clinical trials aimed at enhancing the immune system's ability to combat cancer [1] Offering Details - The offering consisted of 7,637,931 shares of common stock sold at a public offering price of $58.00 per share, along with 293,103 pre-funded warrants sold at $57.9999 each [1] - Gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions [1] - Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering, with Oppenheimer & Co. and H.C. Wainwright & Co. as lead managers [1]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Core Viewpoint - Nektar Therapeutics has announced the pricing of an upsized public offering of $400 million, which includes common stock and pre-funded warrants, aimed at supporting its clinical development and general corporate purposes [1][2] Group 1: Offering Details - Nektar is offering 6,603,449 shares of common stock at a price of $58.00 per share and 293,103 pre-funded warrants at a price of $57.9999 each, leading to expected gross proceeds of approximately $400 million before expenses [1] - The underwriters have a 30-day option to purchase an additional 1,034,482 shares at the public offering price [1] - The offering is expected to close on February 13, 2026, subject to customary conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including research and development, clinical development (notably Phase 3 trials for rezpegaldesleukin), and manufacturing costs [1] Group 3: Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for autoimmune and chronic inflammatory diseases [1] - The lead product candidate, rezpegaldesleukin, is being evaluated in multiple clinical trials for conditions such as atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus [1] - Nektar's pipeline includes additional candidates like NKTR-0165, NKTR-0166, and NKTR-422, as well as NKTR-255, which is designed to enhance the immune system's ability to combat cancer [1]

Core Viewpoint - Nektar Therapeutics (NKTR) shares experienced a significant increase of 51.1% in the last trading session, closing at $56, following the announcement of positive clinical data [1][2]. Group 1: Company Performance - The stock's recent rally was driven by positive data from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study, which evaluated rezpeg in patients with moderate-to-severe atopic dermatitis, showing durable responses across key disease measurements [2]. - The safety profile of rezpeg during the maintenance phase was consistent with that observed in the induction phase of the study [2]. - Nektar is expected to report a quarterly loss of $2.69 per share, reflecting a year-over-year decline of 19.6%, with revenues projected at $9.06 million, down 68.9% from the previous year [3]. Group 2: Market Sentiment and Estimates - The consensus EPS estimate for Nektar has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. - Nektar currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Merck KGaA, has a Zacks Rank of 2 (Buy) and finished the last trading session 1.2% higher [5][6].

Core Insights - Nektar Therapeutics' stock experienced a significant surge following the release of long-term data indicating that its experimental eczema therapy provides sustained and deepening disease control over one year, enhancing its competitive position in the atopic dermatitis market [1] Group 1: Clinical Data and Efficacy - The 36-week blinded maintenance period of the 52-week REZOLVE-AD study showed that the dosing regimens resulted in sustained disease control, with notable improvements in Eczema Area Severity Index (EASI) scores and Itch Numerical Rating Scale (NRS) responses [2][3] - A significant proportion of patients achieved new EASI-75, EASI-90, Itch NRS, and validated Investigator Global Assessment of Atopic Dermatitis (vIGA-AD) responses at Week 52, indicating enhanced disease control with prolonged therapy and less frequent dosing [4] - Monthly maintenance dosing increased EASI-100 response from 4% to 22%, while quarterly dosing increased it from 9% to 18% among re-randomized patients [5] Group 2: Analyst Upgrades and Market Position - William Blair upgraded Nektar Therapeutics to Outperform, citing the deepening of response and durability of the therapy as key factors [6] - The analyst noted that approximately 20% of patients achieved complete disease clearance (EASI-100) after re-randomization, with about 30% achieving this among those who had a prior response [6] - EASI-75 and EASI-90 scores showed remarkable similarity, with quarterly dosing maintaining a higher response rate compared to competitor datasets [7] Group 3: Financial Developments - Nektar Therapeutics initiated a public offering to raise $300 million through equity [8] - The stock closed at $56.00, reflecting a 51.07% increase in regular trading, and continued to rise to $59.10 in early trading [8]